Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 127
interventional 102
Observational 24
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 65
Drug|Other 11
Drug|placebo 4
Biological 3
Drug|Other|Procedure|Radiation 3
Drug|Procedure 2
Other|Procedure 2
Biological|Device|Drug|Procedure|Radiation 1
Biological|Drug|Other|Procedure 1
Biological|Drug|Procedure|Radiation 1
Biological|Genetic|Other|Procedure 1
Biological|Other 1
Device 1
Diagnostic Test 1
Drug|Genetic|Other|Procedure 1
Drug|placebo|Procedure 1
Drug|Radiation 1
Other 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 50
France 4
Japan 4
Denmark 3
United States|Canada 3
United Kingdom 2
United States|Australia|Canada 2
United States|Italy 2
Algeria|Argentina|Austria|Belgium|Brazil|Canada|Colombia|Czechia|Germany|Greece|Hungary|Ireland|Israel|Italy|Mexico|Morocco|Poland|Portugal|Russian Federation|Saudi Arabia|Slovakia|South Africa|Spain|Thailand|Tunisia 1
Australia|Austria|Belgium|China|Czechia|France|Germany|Hungary|Ireland|Italy|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|United Kingdom 1
Australia|Belgium|Bulgaria|Chile|China|Germany|Greece|Hungary|Israel|Italy|Japan|Korea, Republic of|Lebanon|Mexico|Portugal|Russian Federation|South Africa|Spain|Sweden|Thailand|Turkey 1
Australia|Belgium|Canada|Denmark|France|Germany|Ireland|Italy|Netherlands|Spain|United Kingdom 1
Austria|Belgium|Bulgaria|Canada|Germany|Greece|Italy|Japan|Russian Federation|Spain|Turkey 1
Austria|Bulgaria|Croatia|Lithuania|Poland|Romania|Russian Federation|Slovakia|Ukraine 1
Austria|Bulgaria|Lithuania|Poland|Russian Federation 1
Austria|Czech Republic|France|Germany|Hungary|Italy|Lithuania|Poland|Singapore|Slovenia 1
Bulgaria|France|Hungary|Poland|Portugal|Serbia 1
Canada 1
China 1
China|Japan|Korea, Republic of|Taiwan 1
France|Germany|Ireland|Italy|United Kingdom 1
Germany 1
Korea, Republic of 1
Qatar 1
Spain|Sweden|United Kingdom 1
Switzerland 1
United States|Australia 1
United States|Australia|Austria|Belgium|Bulgaria|Canada|Czechia|Denmark|France|Germany|Hungary|Israel|Japan|Korea, Republic of|Netherlands|Poland|Romania|Singapore|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Denmark|France|Germany|Hungary|Israel|Italy|Korea, Republic of|New Zealand|Poland|Singapore|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Bulgaria|Canada|Denmark|France|Germany|Hungary|Israel|Italy|Korea, Republic of|Netherlands|Poland|Romania|Singapore|Spain|Taiwan|United Kingdom 1
United States|Australia|Canada|France|Germany 1
United States|Australia|Canada|France|Germany|Italy|Korea, Republic of|Spain|United Kingdom 1
United States|Australia|Germany|Italy|United Kingdom 1
United States|Belarus|Canada|Czechia|France|Georgia|Germany|Hungary|Israel|Italy|Korea, Republic of|Poland|Russian Federation|Serbia|Spain|Ukraine|United Kingdom 1
United States|Canada|Czechia|France|Germany|Hungary|Poland|Spain|United Kingdom 1
United States|Canada|France|Germany|Israel|Italy|Netherlands|United Kingdom 1
United States|Canada|France|Germany|Israel|Italy|Spain|United Kingdom 1
United States|France 1
United States|France|Italy|United Kingdom 1
United States|Germany|Switzerland 1

Sites per Study

Site_count Study_Count
1 35
2 9
3 5
4 1
5 5
6 4
7 2
8 1
9 2
10 3
11 3
12 1
13 1
15 1
16 1
18 1
19 2
20 1
21 3
22 1
23 1
24 1
25 1
26 1
27 1
29 1
35 2
37 1
38 1
48 1
53 1
65 1
67 1
76 1
96 1
104 1
114 1
124 1
273 1

Phase

Phase Study_Count
Phase 2 42
Phase 1 18
Phase 3 16
Phase 1/Phase 2 10
N/A 9
Phase 4 5
Early Phase 1 1
Phase 2/Phase 3 1

Number of Arms

Number_of_Arms Count_of_Studies
1 61
2 25
3 5
4 7
5 2
6 1
NA 1

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 72 5.0000 10.00000 37.00 8.00000 13 41.0 40.0
1st Qu. 72 30.0000 23.25000 47.25 36.00000 13 108.0 48.0
Median 72 52.0000 33.00000 52.50 52.50000 13 168.0 70.0
Mean 72 207.6667 39.88889 73.50 81.78571 13 444.4 132.8
3rd Qu. 72 102.0000 60.75000 73.00 114.50000 13 274.0 150.0
Max. 72 1398.0000 100.00000 166.00 400.00000 13 2250.0 356.0

Trial Group Type

group_type Group_Count
Experimental 134
Active Comparator 27
Other 7
Placebo Comparator 1
Sham Comparator 1
NA 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 61
Parallel Assignment 36
Sequential Assignment 3
Crossover Assignment 1
NA 1

Primary Purpose

primary_purpose Study_Count
Treatment 92
Supportive Care 3
Diagnostic 2
Screening 2
Other 1
Prevention 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
United States 5
France 4
Italy 2
Taiwan 2
United States|Italy 2
Czech Republic|France|Germany|Greece|Italy|Spain|Switzerland|United Kingdom 1
Czechia|Germany|Israel|Italy|Spain|United Kingdom 1
Denmark|Finland|France|Germany|Greece|Ireland|Italy|Netherlands|Norway|Portugal|Spain|Sweden|United Kingdom 1
Denmark|Hungary 1
Japan 1
NA 1
Switzerland|United Kingdom 1
United States|Canada|Italy|United Kingdom 1
United States|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 10
2 3
6 1
7 1
10 1
11 1
22 1
30 1
32 1
46 1
116 1
164 1
488 1

Enrollment Metrics

Measure Observational
Min 8.0000
1st Qu 80.5000
Median 186.5000
Mean 621.8636
3rd Qu 903.7500
Max 3647.0000

Observation Model

observational_model Study_Count
Cohort 10
Case-Only 5
Case-Control 3
Other 3
NA 2
Family-Based 1

Time Perspective

time_perspective Study_Count
Prospective 12
Retrospective 6
Other 3
Cross-Sectional 2
NA 1

Registries

Studies by Country

Country Study_Count
Canada 1

Sites per Study

Site_count Study_Count
1 1

Enrollment Metrics

Measure Registries
Min 5000
1st Qu 5000
Median 5000
Mean 5000
3rd Qu 5000
Max 5000

Registry Model

observational_model Study_Count
Cohort 1

Time Perspective

time_perspective Study_Count
Other 1

Follow-up

target_duration Study_Count
10 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04173494 A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM) https://ClinicalTrials.gov/show/NCT04173494 Recruiting Sierra Oncology, Inc. 2021-12-31
NCT03289910 Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT03289910 Recruiting National Cancer Institute (NCI) 2021-06-01
NCT03232177 Anagre Cap. in Patients With High-Risk Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT03232177 Recruiting Yuhan Corporation 2021-06-30
NCT03212053 Prospective Study of Different Biological Tests (Multiplate, ROTEM) in a Cohort of Patients Followed for Essential Thrombocytemia (ET) https://ClinicalTrials.gov/show/NCT03212053 Completed Hospices Civils de Lyon 2019-08-08
NCT03136185 IMG-7289 in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT03136185 Recruiting Imago BioSciences,Inc. 2020-12-31
NCT03123588 Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) https://ClinicalTrials.gov/show/NCT03123588 Recruiting Incyte Corporation 2020-05-31
NCT03116542 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT03116542 Recruiting Hamad Medical Corporation 2020-05-31
NCT03065400 PD-1 Inhibition in Advanced Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT03065400 Completed Icahn School of Medicine at Mount Sinai 2020-05-28
NCT02966353 Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. https://ClinicalTrials.gov/show/NCT02966353 Completed Novartis 2018-07-24
NCT02962388 The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line https://ClinicalTrials.gov/show/NCT02962388 Active, not recruiting French Innovative Leukemia Organisation 2018-06-07
NCT02611973 Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT02611973 Recruiting Assistance Publique - Hôpitaux de Paris 2019-11-30
NCT03165734 A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis https://ClinicalTrials.gov/show/NCT03165734 Recruiting CTI BioPharma 2022-07-31
NCT01433445 Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis https://ClinicalTrials.gov/show/NCT01433445 Completed Novartis 2020-06-22
NCT02556931 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies https://ClinicalTrials.gov/show/NCT02556931 Active, not recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2021-07-31
NCT02515630 Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) https://ClinicalTrials.gov/show/NCT02515630 Completed Sierra Oncology, Inc. 2017-07-18
NCT02436135 Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease https://ClinicalTrials.gov/show/NCT02436135 Completed Gilead Sciences 2017-11-20
NCT02407080 Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT02407080 Completed Icahn School of Medicine at Mount Sinai 2018-12-19
NCT02386800 CINC424A2X01B Rollover Protocol https://ClinicalTrials.gov/show/NCT02386800 Recruiting Novartis 2025-09-17
NCT02311569 Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation https://ClinicalTrials.gov/show/NCT02311569 Completed Swiss Group for Clinical Cancer Research 2016-12-31
NCT02129101 Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies https://ClinicalTrials.gov/show/NCT02129101 Completed Mayo Clinic 2016-12-31
NCT02125318 A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders https://ClinicalTrials.gov/show/NCT02125318 Completed Galena Biopharma, Inc. 2016-05-31
NCT02124746 Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT02124746 Completed Sierra Oncology, Inc. 2018-12-06
NCT02101268 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF https://ClinicalTrials.gov/show/NCT02101268 Completed Sierra Oncology, Inc. 2016-07-28
NCT02098161 LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis https://ClinicalTrials.gov/show/NCT02098161 Active, not recruiting M.D. Anderson Cancer Center 2020-12-31
NCT02087059 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis https://ClinicalTrials.gov/show/NCT02087059 Completed Novartis 2015-03-31
NCT02076815 Anagrelide Retard in Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT02076815 Completed AOP Orphan Pharmaceuticals AG 2015-02-28
NCT01369498 Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis https://ClinicalTrials.gov/show/NCT01369498 Completed Gilead Sciences 2014-06-05
NCT01981850 A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis https://ClinicalTrials.gov/show/NCT01981850 Active, not recruiting Promedior, Inc. 2017-08-30
NCT01969838 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis https://ClinicalTrials.gov/show/NCT01969838 Completed Sierra Oncology, Inc. 2016-09-12
NCT01816256 Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT01816256 Completed University Health Network, Toronto 2019-03-11
NCT01787552 A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF https://ClinicalTrials.gov/show/NCT01787552 Completed Novartis 2018-04-10
NCT01787487 Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm https://ClinicalTrials.gov/show/NCT01787487 Recruiting M.D. Anderson Cancer Center 2020-07-26
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01692366 Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly https://ClinicalTrials.gov/show/NCT01692366 Completed Sanofi 2014-03-31
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT01558739 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) https://ClinicalTrials.gov/show/NCT01558739 Completed Novartis 2014-01-31
NCT01520220 Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT01520220 Completed Eli Lilly and Company 2015-06-26
NCT01493414 INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. https://ClinicalTrials.gov/show/NCT01493414 Completed Novartis 2017-01-26
NCT01467661 Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia https://ClinicalTrials.gov/show/NCT01467661 Completed Shire 2015-05-01
NCT01445769 Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT01445769 Completed Incyte Corporation 2013-03-31
NCT01423851 Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF https://ClinicalTrials.gov/show/NCT01423851 Active, not recruiting NS Pharma, Inc. 2020-11-30
NCT01420783 Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT01420783 Completed Sanofi 2012-11-30
NCT01392443 Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF https://ClinicalTrials.gov/show/NCT01392443 Completed Novartis 2017-10-31
NCT01387763 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms https://ClinicalTrials.gov/show/NCT01387763 Active, not recruiting Odense University Hospital 2020-01-31
NCT01384513 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01384513 Recruiting Thomas Jefferson University 2020-12-31
NCT01348490 Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) https://ClinicalTrials.gov/show/NCT01348490 Completed Incyte Corporation 2018-12-19
NCT03878524 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial https://ClinicalTrials.gov/show/NCT03878524 Recruiting OHSU Knight Cancer Institute 2022-02-27
NCT04282187 Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT04282187 Recruiting University of Washington 2024-11-11
NCT04262141 IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) https://ClinicalTrials.gov/show/NCT04262141 Recruiting University of Miami 2023-08-31
NCT04226950 Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Childhood Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT04226950 Recruiting Institute of Hematology & Blood Diseases Hospital 2022-07-20
NCT04081220 Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 https://ClinicalTrials.gov/show/NCT04081220 Recruiting The University of Texas Health Science Center at San Antonio 2022-01-31
NCT03972943 CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT03972943 Recruiting University of Utah 2024-05-01
NCT03952039 An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib https://ClinicalTrials.gov/show/NCT03952039 Recruiting Celgene 2021-11-24
NCT03935555 Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib https://ClinicalTrials.gov/show/NCT03935555 Recruiting Samus Therapeutics, Inc. 2020-05-15
NCT03907436 The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase https://ClinicalTrials.gov/show/NCT03907436 Completed University of California, Irvine 2019-10-01
NCT03895112 MPN-RC 118 AVID200 in Myelofibrosis https://ClinicalTrials.gov/show/NCT03895112 Recruiting Icahn School of Medicine at Mount Sinai 2021-03-31
NCT03878199 Ruxolitinib and Daunorubicin (CPX-351) in Treating Patients With Secondary Acute Myeloid Leukemia Transformed From Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT03878199 Recruiting OHSU Knight Cancer Institute 2021-12-31
NCT03869476 Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. https://ClinicalTrials.gov/show/NCT03869476 Recruiting University Hospital, Angers 2023-06-30
NCT03862157 Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT03862157 Recruiting M.D. Anderson Cancer Center 2024-01-01
NCT03755518 An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib https://ClinicalTrials.gov/show/NCT03755518 Recruiting Celgene 2022-05-19
NCT03662126 KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor https://ClinicalTrials.gov/show/NCT03662126 Recruiting Kartos Therapeutics, Inc. 2021-08-01
NCT03627403 Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors https://ClinicalTrials.gov/show/NCT03627403 Recruiting University of Utah 2024-03-14
NCT03566446 CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT03566446 Active, not recruiting Herlev Hospital 2020-02-20
NCT03441113 Extended Access of Momelotinib in Adults With Myelofibrosis https://ClinicalTrials.gov/show/NCT03441113 Enrolling by invitation Sierra Oncology, Inc. 2024-12-31
NCT01259856 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) https://ClinicalTrials.gov/show/NCT01259856 Completed Icahn School of Medicine at Mount Sinai 2017-06-30
NCT01259817 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) https://ClinicalTrials.gov/show/NCT01259817 Completed Icahn School of Medicine at Mount Sinai 2016-12-31
NCT01243073 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera https://ClinicalTrials.gov/show/NCT01243073 Completed Geron Corporation 2013-10-31
NCT01236638 Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) https://ClinicalTrials.gov/show/NCT01236638 Completed Sierra Oncology, Inc. 2014-06-30
NCT01230775 Anagrelide Retard vs. Placebo: Efficacy and Safety in “At-risk” Patients With Essential Thrombocythaemia https://ClinicalTrials.gov/show/NCT01230775 Completed AOP Orphan Pharmaceuticals AG 2015-01-31
NCT01214915 Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia https://ClinicalTrials.gov/show/NCT01214915 Completed Shire 2012-10-24
NCT01134120 A Study in Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT01134120 Completed Eli Lilly and Company 2014-04-30
NCT01065038 Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia https://ClinicalTrials.gov/show/NCT01065038 Completed AOP Orphan Pharmaceuticals AG NA
NCT01053494 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer https://ClinicalTrials.gov/show/NCT01053494 Completed Wake Forest University Health Sciences 2012-02-29
NCT00946270 Pomalidomide for Myelofibrosis Patients https://ClinicalTrials.gov/show/NCT00946270 Completed M.D. Anderson Cancer Center 2018-05-22
NCT00935987 Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) https://ClinicalTrials.gov/show/NCT00935987 Completed Sierra Oncology, Inc. 2012-04-30
NCT00910728 Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases https://ClinicalTrials.gov/show/NCT00910728 Completed AstraZeneca 2012-03-31
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT01423058 Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis https://ClinicalTrials.gov/show/NCT01423058 Completed Sierra Oncology, Inc. 2014-06-30
NCT04051307 Dual Vaccine Trial in Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT04051307 Recruiting Herlev Hospital 2022-07-10
NCT02577926 The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT02577926 Recruiting RWTH Aachen University 2020-12-31
NCT03373877 Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis https://ClinicalTrials.gov/show/NCT03373877 Active, not recruiting Samus Therapeutics, Inc. 2020-10-31
NCT04254978 IMG-7289 in Patients With Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT04254978 Recruiting Imago BioSciences,Inc. 2022-05-31
NCT00745550 A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis https://ClinicalTrials.gov/show/NCT00745550 Completed S*BIO 2012-01-31
NCT00718159 Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00718159 Completed Eli Lilly and Company 2011-12-31
NCT00588991 Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00588991 Active, not recruiting National Cancer Institute (NCI) 2014-02-01
NCT00586651 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis https://ClinicalTrials.gov/show/NCT00586651 Completed Teva Pharmaceutical Industries 2009-10-31
NCT00509899 Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis https://ClinicalTrials.gov/show/NCT00509899 Completed Incyte Corporation 2007-12-31
NCT00489203 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00489203 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00445744 Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT00445744 Completed Fred Hutchinson Cancer Research Center 2011-06-30
NCT00413634 The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) https://ClinicalTrials.gov/show/NCT00413634 Completed Shire 2008-01-31
NCT00397813 Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00397813 Completed Fred Hutchinson Cancer Research Center 2017-09-30
NCT00381550 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00381550 Completed National Cancer Institute (NCI) 2011-03-31
NCT00357305 Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00357305 Completed National Cancer Institute (NCI) 2011-11-30
NCT00227591 Lenalidomide and Prednisone in Treating Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT00227591 Completed National Cancer Institute (NCI) 2010-12-31
NCT00202644 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients https://ClinicalTrials.gov/show/NCT00202644 Completed Shire 2015-12-15
NCT00175838 Primary Thrombocythaemia 1 Trial https://ClinicalTrials.gov/show/NCT00175838 Completed University of Cambridge 2016-11-30
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00089011 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00089011 Completed Fred Hutchinson Cancer Research Center 2014-03-31
NCT00047190 Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia https://ClinicalTrials.gov/show/NCT00047190 Completed National Cancer Institute (NCI) 2007-04-30
NCT00039416 Imatinib Mesylate in Treating Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT00039416 Completed National Cancer Institute (NCI) 2007-08-31
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00052520 Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00052520 Completed Fred Hutchinson Cancer Research Center 2011-04-30

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT02912884 Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure https://ClinicalTrials.gov/show/NCT02912884 Active, not recruiting University Hospital, Geneva 2020-07-31
NCT02897297 Myeloproliferative Neoplastic Diseases Observatory From Brest https://ClinicalTrials.gov/show/NCT02897297 Recruiting University Hospital, Brest 2025-09-30
NCT02893410 Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients https://ClinicalTrials.gov/show/NCT02893410 Completed University Hospital, Brest 2015-12-31
NCT02823184 Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT02823184 Completed University Hospital, Bordeaux 2019-04-27
NCT02308787 Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions https://ClinicalTrials.gov/show/NCT02308787 Completed Terumo BCT 2015-05-31
NCT01970930 Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients https://ClinicalTrials.gov/show/NCT01970930 Completed Icahn School of Medicine at Mount Sinai 2016-06-02
NCT01352585 Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID® https://ClinicalTrials.gov/show/NCT01352585 Completed Shire 2013-09-19
NCT03828422 Arterial Function and Atherosclerosis in Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT03828422 Active, not recruiting University Medical Centre Ljubljana 2019-07-31
NCT03745378 Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) https://ClinicalTrials.gov/show/NCT03745378 Completed Fondazione per la Ricerca Ospedale Maggiore 2018-07-07
NCT03717519 Elevated Platelet Count as Prognostic Factor in Colorectal Cancer With Synchronous Liver Metastases https://ClinicalTrials.gov/show/NCT03717519 Completed Azienda Ospedaliera Universitaria Integrata Verona 2018-05-01
NCT03625895 Agrylin Drug Use-Result Survey https://ClinicalTrials.gov/show/NCT03625895 Completed Shire 2017-12-08
NCT01230528 Childhood Reactive Thrombocytosis https://ClinicalTrials.gov/show/NCT01230528 Completed Taipei Medical University WanFang Hospital 2010-01-31
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01198717 Pediatric Disease Registry in Essential Thrombocythaemia (ET) https://ClinicalTrials.gov/show/NCT01198717 Completed Shire 2016-03-31
NCT01194349 The Role of Reactive Thrombocytosis in Children With Pneumococcal Infection https://ClinicalTrials.gov/show/NCT01194349 Completed Taipei Medical University WanFang Hospital NA
NCT01192347 French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT01192347 Completed Shire 2012-10-31
NCT02953704 Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) https://ClinicalTrials.gov/show/NCT02953704 Active, not recruiting Incyte Corporation 2022-03-31
NCT00722527 Molecular Biology of Polycythemia and Thrombocytosis https://ClinicalTrials.gov/show/NCT00722527 Recruiting University of Utah 2020-07-31
NCT00715247 Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes https://ClinicalTrials.gov/show/NCT00715247 Completed University of Utah 2018-12-31
NCT00666549 Research Tissue Bank https://ClinicalTrials.gov/show/NCT00666549 Completed Icahn School of Medicine at Mount Sinai 2017-03-27
NCT00666289 Familial Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00666289 Completed Icahn School of Medicine at Mount Sinai 2015-01-20
NCT00665067 Correlative Biomarker Study in Patients With Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00665067 Completed Icahn School of Medicine at Mount Sinai 2018-07-20
NCT00567502 Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments https://ClinicalTrials.gov/show/NCT00567502 Completed Shire 2014-04-30
NCT00433862 Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00433862 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02760238 Myeloproliferative Neoplasms (MPNs) Patient Registry https://ClinicalTrials.gov/show/NCT02760238 Recruiting University Health Network, Toronto 2025-10-31